Navigation Links
Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
Date:1/28/2009

the six months ended December 31, 2008 when compared with $12.6 million in the comparable prior fiscal year period. Royalty income in the first six months of fiscal 2009 included $10.6 million in Angio-Seal(TM) royalties and $2.8 million in royalties from Orthovita, Inc. (Nasdaq: VITA). Angio-Seal royalties were up 2% from the comparable six months of the prior fiscal year. Orthovita royalties increased 33% which was attributable to the recent successful introduction by Orthovita of its new VITOSS(R) Bioactive Foam products, as well as the continuing sales of existing VITOSS(R) FOAM products by Orthovita in the end-user marketplace.

Earnings Per Share. The Company reported diluted earnings per share of $0.87 for the six months ended December 31, 2008, which represented an increase of 142% when compared with the $0.36 adjusted diluted earnings per share* for the same period in fiscal 2008. Adjusted diluted earnings per share for the first six months of fiscal 2008 exclude after-tax charges of $2.2 million, or $0.17 per share, for the acceleration of stock awards and discontinuation of the Company's embolic protection platform. Including these items, diluted earnings per share increased 358% in the first six months of fiscal 2009 over the fiscal 2008 comparable period reported diluted earnings per share of $0.19.

In the six-month period ended December 31, 2008, the total tax-effected impact on earnings per share of equity compensation expense was $0.02, which included a favorable mark-to-market adjustment on stock appreciation rights. In the six-month period ended December 31, 2007, the total tax-effected impact on earnings per share of equity compensation expense was $0.23, of which $0.16 related to the acceleration of stock awards and $0.08 related to equity compensation expense prior to the acceleration, equity comp
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
3. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
4. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
7. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
8. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
9. GEN Reports on Growing Reliance on Microfluidics Technology
10. Novozymes Reports Strong 2008 Results
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 A Geisinger researcher on ... for a Centers for Disease Control and Prevention (CDC) ... public health concern. Joseph Boscarino , ... of a team of researchers nominated for the Centers ... Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... 19, 2014 Robin Williams’ passing is ... take on an individual. Symptoms range from slowness ... problems swallowing and severe depression. Parkinson’s disease progressively ... of dopamine producing neurons of the brain. As ... that slowly and progressively gets worse, they look for ...
(Date:8/19/2014)... Md. , Aug. 19, 2014 CSSi, ... research industry, recently announced the formation of the company,s ... to announce the addition of Dr. William E. ... - http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, ... a variety of therapeutic areas and set strategic goals ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... ... most complex toxicology study designs in South Korea , ... Cedar Knolls, NJ and Daejeon, South Korea (PRWEB) ... solutions and the developer of Pristima™ the premier preclinical solution on the market, is ...
... , , ABBOTT PARK, Ill., Aug. ... expansion of the company,s XIENCE V(R) USA post-approval study designed to ... Everolimus Eluting Coronary Stent System in a real-world clinical setting out ... from the XIENCE V USA trial to be eligible to cross ...
... , , , ... MON ) R&D pipeline is on the verge of a technology ... for growers and has the company poised to meet its goals ... and president, will tell investors today. , , ...
Cached Biology Technology:Korea Institute of Toxicology Implementing Xybion's Pristima™ 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 3Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7
(Date:8/20/2014)... leaves, photosystem 1 (PS1) absorbs light and its ... carbon dioxide to biomass. Photovoltaic devices, mostly build ... but produce electricity. One approach for the development ... the semi-conductor with the isolated membrane protein complexes ... a highly stable PS1 from thermophilic cyanobacteria that ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... This news release is available in German . ... power are inherently intermittent energy sources. If a large amount ... in the future, excess energy will have to be stored ... for. However, existing storage capacities are far from adequate for ... better technologies. One important focus lies on battery systems that ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... A) today announced that its breakthrough Human Genome CGH ... Peter MacCallum Cancer Centre in a three-year study designed ... lining of the chest, the abdominal cavity and around ... Due to its active mining and manufacturing of asbestos ...
... The human fossil evidence from the Mladec Caves in Moravia, ... proven for the first time, through modern radiocarbon dating, to ... modern humans in Europe. , A team of researchers from ... Vienna in Austria and from the Washington University in St. ...
... Studying phage, a primitive class of virus that infects ... researchers have gained insight into the driving force behind ... in the past to occur through the release of ... all phages (also known as bacteriophages) are formed of ...
Cached Biology News:Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma 2Oldest cranial, dental and postcranial fossils of early modern European humans confirmed 2Basis for DNA ejection from single phage particles 2
...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant canine ... culture supernates and serum.1 Each kit contains ... fifteen 96-well plates, provided that the following ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu™ Insertion Kit...
Biology Products: